Second International Study of Infarct Survival

Second International Study of Infarct Survival (ISIS-2)," Eaneetii, 349 (1988). 

Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R, for the ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. ISIS-2 10 year... 

ISIS-2 (1988) (Second International Study of Infarct Survival) Collaborative Group Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17, 187 cases of suspected acute myocardial infarction ISIS-2. Lancet 2 349-360. 

INTERCEPT Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis ISIS-1 First International Study of Infarct Survival ISIS-2 Second International Study of Infarct Survival IV intravenous LDL low-density lipoprotein LMWH low-molecular-weight heparin LVEF left ventricular ejection fraction MB myocardial band MI myocardial infarction... 

The second study was the European International Study of Infarct Survival (ISIS II) Trial (11). This study randomized patients suspected of having an AMI (there were no ECG inclusion criteria) to one of four arms placebo, aspirin only, streptokinase only, or streptokinase plus aspirin. Thus, this was the first large trial of combination therapy to evaluate the impact of treating both the fibrin and the platelet components of clot. Of 17,187 patients randomized, mortality at 30 days was lowered by 21% in those treated with streptokinase, from 13.2% in the placebo group to 10.4%, with a similar 19% reduction to 10.7% in those treated with aspirin alone. Those receiving both agents had a 39% reduction in mortality to 8.0% (p < 0.05 for all comparisons). These patients were enrolled up to 24 hours after symptom onset, and the median time to treatment was 5 hours. Heparin therapy was not included in the protocol regimen. 

---